Adoptive T-cell immunotherapy

Current Topics in Microbiology and Immunology

Volumn 391, Issue , 2015, Pages 427-454

  Gottschalk, Stephen ^a   Rooney, Cliona M ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALEMTUZUMAB; B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS VACCINE; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RANTES; RITUXIMAB; TOLL LIKE RECEPTOR 4; VARICELLA ZOSTER VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CELL HOMING; DNA MODIFICATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE TRANSFER; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNE EVASION; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; T LYMPHOCYTE; TH2 CELL; TUMOR MICROENVIRONMENT; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION; ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; GENETICS; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES;

EID: 84943245611     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/978-3-319-22834-1_15     Document Type: Chapter

References (139)

1. Apcher S, Daskalogianni C, Manoury B et al (2010) Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation. PLoS Pathog 6(10):e1001151
2. Barker JN, Doubrovina E, Sauter C et al (2010) Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 116(23):5045-5049
3. Bollard CM, Rossig C, Calonge MJ et al (2002) Adapting a transforming growth factor betarelated tumor protection strategy to enhance antitumor immunity. Blood 99(9):3179-3187
4. Bollard CM, Aguilar L, Straathof KC et al (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 200(12):1623-1633
5. Bollard CM, Gottschalk S, Leen AM et al (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110(8):2838-2845
6. Bollard CM, Dotti G, Gottschalk S et al (2012) Administration of TGF-beta resistant tumor-specific CTL to patienst with EBV-associated HL and NHL. Mol Ther 20(Supplement 1):S22
7. Bollard CM, Gottschalk S, Torrano V et al (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32(8):798-808
8. Bonini C, Brenner MK, Heslop HE et al (2011) Genetic modification of T cells. Biol Blood Marrow Transplant 17(1 Suppl):S15-S20
9. Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455-2465
10. Brentjens RJ, Davila ML, Riviere I et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5(177):177ra38
11. Brewin J, Mancao C, Straathof K et al (2009) Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 114(23):4792-4803
12. Brooks L, Yao QY, Rickinson AB et al (1992) Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 66(5):2689-2697
13. Buettner M, Meyer B, Schreck S et al (2007) Expression of RANTES and MCP-1 in epithelial cells is regulated via LMP1 and CD40. Int J Cancer 121(12):2703-2710
14. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S et al (2012) Gene therapy for primary immunodeficiencies: Part 1. Curr Opin Immunol 24(5):580-584
15. Chan AT, Tao Q, Robertson KD et al (2004) Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 22(8):1373-1381
16. Chen L, Huang TG, Meseck M et al (2007) Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther 15(12):2194-2202
17. Chia WK, Teo M, Wang WW et al (2014) Adoptive T-cell transfer and chemotherapy in the firstline treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22(1):132-139
18. Chiang AK, Tao Q, Srivastava G et al (1996) Nasal NK-and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 68(3):285-290
19. Chinnasamy D, Yu Z, Kerkar SP et al (2012) Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 18(6):1672-1683
20. Chua D, Huang J, Zheng B et al (2001) Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer 94(1):73-80
21. Cobbold M, Khan N, Pourgheysari B et al (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202(3):379-386
22. Cobbold M, De La Pena H, Norris A et al (2013) MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med 5(203):203ra125
23. Comoli P, Locatelli F, Gerna G et al (1997) Autologous EBV-specific cytotoxic T cells to treat EBV-associated post-transplant lymphoproliferative disease (PTLD). Blood 90(10):249a
24. Comoli P, Labirio M, Basso S et al (2002) Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99(7):2592-2598
25. Comoli P, Pedrazzoli P, Maccario R et al (2005) Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23(35):8942-8949
26. Conlon KC, Lugli E, Welles HC et al (2014) Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 33:74-84
27. Cruz CR, Micklethwaite KP, Savoldo B et al (2013) Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122(17):2965-2973
28. Cruz-Merino L, Lejeune M, Nogales FE et al (2012) Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications. Clin Dev Immunol 2012:756353
29. DeAngelis B, Dotti G, Quintarelli C et al (2009) Generation of virus-specific cytotoxic T lymphocytes (Ctls) resistant to the immunosuppressive drug tacrolimus (Fk506). Biol Blood Marrow Transplant 15(2):377
30. De AB, Dotti G, Quintarelli C et al (2009) Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 114(23):4784-4791
31. Decaussin G, Sbih-Lammali F, de Turenne-Tessier M et al (2000) Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 60(19):5584-5588
32. DiStasi A, De Angelis B, Rooney CM et al (2009) T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113(25):6392-6402
33. DiStasi A, Tey SK, Dotti G et al (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365(18):1673-1683
34. Dotti G, Savoldo B, Pule M et al (2005) Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 105(12):4677-4684
35. Dotti G, Gottschalk S, Savoldo B et al (2014) Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257(1):107-126
36. Doubrovina E, Oflaz-Sozmen B, Prockop SE et al (2012) Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119(11):2644-2656
37. Dudley ME, Yang JC, Sherry R et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233-5239
38. Feng WH, Kenney SC (2006) Valproic acid enhances the efficacy of chemotherapy in EBVpositive tumors by increasing lytic viral gene expression. Cancer Res 66(17):8762-8769
39. Feng WH, Hong G, Delecluse HJ et al (2004) Lytic induction therapy for Epstein-Barr viruspositive B-cell lymphomas. J Virol 78(4):1893-1902
40. + T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol 32(3):282-289
41. Feuchtinger T, Opherk K, Bethge WA et al (2010) Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116(20):4360-4367
42. Fiorini S, Ooka T (2008) Secretion of Epstein-Barr virus-encoded BARF1 oncoprotein from latently infected B cells. Virol J 5:70
43. + T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc Natl Acad Sci USA 106(9):3318-3323
44. + T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma. Virology 441(2):107-113
45. Foster AE, Dotti G, Lu A et al (2008) Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 31(5):500-505
46. Gahn B, Siller-Lopez F, Pirooz AD et al (2001) Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to the LMP2A-antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer 93(5):706-713
47. Gerdemann U, Christin AS, Vera JF et al (2009) Nucleofection of DCs to generate Multivirusspecific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther 17(9):1616-1625
48. Gerdemann U, Keirnan JM, Katari UL et al (2012) Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 20(8):1622-1632
49. Gerdemann U, Katari UL, Papadopoulou A et al (2013) Safety and clinical efficacy of rapidlygenerated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 21(11):2113-2121
50. Gilligan KJ, Rajadurai P, Lin JC et al (1991) Expression of the Epstein-Barr virus BamHI a fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol 65(11):6252-6259
51. Gottschalk S, Edwards OL, Sili U et al (2003) Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 101(5):1905-1912
52. Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509-1518
53. Hacein-Bey-Abina S, Hauer J, Lim A et al (2010) Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363(4):355-364
54. Haque T, Amlot PL, Helling N et al (1998) Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 160(12):6204-6209
55. Haque T, Wilkie GM, Taylor C et al (2002) Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360(9331):436-442
56. Haque T, Wilkie GM, Jones MM et al (2007) Allogeneic cytotoxic T-cell therapy for EBVpositive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110(4):1123-1131
57. Herbst H, Dallenbach F, Hummel M et al (1991) Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 88(11):4766-4770
58. Heslop HE, Ng CYC, Li C et al (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551-555
59. Heslop HE, Slobod KS, Pule MA et al (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5):925-935
60. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723
61. Huye LE, Nakazawa Y, Patel MP et al (2011) Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther 19(12):2239-2248
62. Icheva V, Kayser S, Wolff D et al (2013) Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 31(1):39-48
63. John LB, Devaud C, Duong CP et al (2013) Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19(20):5636-5646
64. Jonnalagadda M, Brown CE, Chang WC et al (2013) Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy. PLoS ONE 8(6):e65519
65. Kalos M, Levine BL, Porter DL et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73
66. Kern F, Faulhaber N, Frommel C et al (2000) Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 30(6):1676-1682
67. Khanna R, Bell S, Sherritt M et al (1999) Activation and adoptive transfer of Epstein-Barr virusspecific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 96(18):10391-10396
68. Lee SP, Brooks JM, Al-Jarrah H et al (2004) CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. J Exp Med 199(10):1409-1420
69. Leen A, Meij P, Redchenko I et al (2001) Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol 75(18):8649-8659
70. Leen AM, Myers GD, Sili U et al (2006) Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12(10):1160-1166
71. Leen AM, Rooney CM, Foster AE (2007) Improving T cell therapy for cancer. Annu Rev Immunol 25:243-265
72. Leen AM, Christin A, Myers GD et al (2009) Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114(19):4283-4292
73. Leen AM, Bollard CM, Mendizabal AM et al (2013) Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121(26):5113-5123
74. Leen AM, Sukumaran S, Watanabe N et al (2014) Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther 22(6):1211-1220
75. Levitskaya J, Coram M, Levitsky V et al (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375(6533):685-688
76. Levitskaya J, Sharipo A, Leonchiks A et al (1997) Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci 94(23):12616-12621
77. + T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders. PLoS Pathog 10(5):e1004068
78. Louis CU, Straathof K, Bollard CM et al (2010) Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 33(9):983-990
79. Louis CU, Savoldo B, Dotti G et al (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118(23):6050-6056
80. Lucas KG, Salzman D, Garcia A et al (2004) Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 100(9):1892-1901
81. Moosmann A, Bigalke I, Tischer J et al (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115(14):2960-2970
82. Moskwa M, Ribrag V, Michot J-M et al (2014) PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study. Blood 24(21):290
83. Mrizak D, Martin N, Barjon C et al (2015) Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. J Natl Cancer Inst 107(1):363
84. Munz C (2004) Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target. J Exp Med 199(10):1301-1304
85. Munz C, Bickham KL, Subklewe M et al (2000) Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 191(10):1649-1660
86. Ngo MC, Ando J, Leen AM et al (2014) Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother 37(4):193-203
87. + T-cell effectors inhibit Epstein-Barr virusinduced B-cell proliferation. J Virol 75(8):3740-3752
88. Pallesen G, Hamilton-Dutoit SJ, Rowe M et al (1991) Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337:320-322
89. Paludan C, Bickham K, Nikiforow S et al (2002) Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol 169(3):1593-1603
90. Papadopoulou A, Gerdemann U, Katari UL et al (2014) Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 6(242):242ra83
91. Peggs KS, Thomson K, Samuel E et al (2011) Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 52(1):49-57
92. Pegram HJ, Lee JC, Hayman EG et al (2012) Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18):4133-4141
93. Perna SK, De AB, Pagliara D et al (2013) Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 19(1):106-117
94. Perna SK, Pagliara D, Mahendravada A et al (2014) Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 20(1):131-139
95. Perrine SP, Hermine O, Small T et al (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109(6):2571-2578
96. Poppema S (2005) Immunobiology and pathophysiology of hodgkin lymphomas. Hematol Am Soc Hematol Educ Program 2005:231-238
97. Porter DL, Roth MS, McGarigle C et al (1994) Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330(2):100-106
98. Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725-733
99. + immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med 201(3):349-360
100. Pule MA, Savoldo B, Myers GD et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14(11):1264-1270
101. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296
102. Ricciardelli I, Blundell MP, Brewin J et al (2014) Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood 124(16):2514-2522
103. Rooney CM, Smith CA, Ng C et al (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345:9-13
104. Rooney CM, Smith CA, Ng CYC et al (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5):1549-1555
105. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21(2):233-240
106. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137(5):1735-1742
107. Rowe M, Rowe DT, Gregory CD et al (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6:2743-2751
108. Savoldo B, Goss J, Liu Z et al (2001) Generation of autologous Epstein Barr virus (EBV)-specific cytotoxic T cells (CTL) for adoptive immunotherapy in solid organ transplant recipients. Transplantation 72(6):1078-1086
109. Savoldo B, Goss JA, Hammer MM et al (2006) Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108(9):2942-2949
110. Savoldo B, Rooney CM, Di Stasi A et al (2007) Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 110(7):2620-2630
111. Secondino S, Zecca M, Licitra L et al (2012) T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol 23(2):435-441
112. Seto E, Yang L, Middeldorp J et al (2005) Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol 76(1):82-88
113. Shaffer DR, Savoldo B, Yi Z et al (2011) T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 117(16):4304-4314
114. Sherritt MA, Bharadwaj M, Burrows JM et al (2003) Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 75(9):1556-1560
115. Shirley CM, Chen J, Shamay M et al (2011) Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood 117(23):6297-6303
116. Smith C, Tsang J, Beagley L et al (2012) Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 72(5):1116-1125
117. Song XT, Turnis M, Zhou X et al (2010) A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther 19(1):211-217
118. Sportes C, Hakim FT, Memon SA et al (2008) Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 205(7):1701-1714
119. Steigerwald-Mullen PM, Klein G, Kurilla MG et al (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375(6533):685-688
120. Steven NM, Annels NE, Kumar A et al (1997) Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 185(9):1605-1617
121. Straathof KC, Bollard CM, Popat U et al (2005a) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105:1898-1904
122. Straathof KC, Pule MA, Yotnda P et al (2005b) An inducible caspase 9 safety switch for T-cell therapy. Blood 105(11):4247-4254
123. Suhoski MM, Golovina TN, Aqui NA et al (2007) Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 15(5):981-988
124. Tellam JT, Lekieffre L, Zhong J et al (2012) Messenger RNA sequence rather than protein sequence determines the level of self-synthesis and antigen presentation of the EBVencoded antigen, EBNA1. PLoS Pathog 8(12):e1003112
125. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454
126. Uhlin M, Gertow J, Uzunel M et al (2012) Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 55(8):1064-1073
127. Vera JF, Hoyos V, Savoldo B et al (2009) Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 17(5):880-888
128. Vickers MA, Wilkie GM, Robinson N et al (2014) Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol 167(3):402-410
129. Vogler I, Newrzela S, Hartmann S et al (2010) An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther 18(7):1330-1338
130. + T lymphocytes. J Exp Med 199(4):459-470
131. Wagner HJ, Bollard CM, Vigouroux S et al (2004) A strategy for treatment of Epstein-Barr viruspositive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther 11(2):81-91
132. Wallace LE, Rickinson AB, Rowe M et al (1982) Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr virus-transformed cell line. I. Virus-specific and nonspecific components of the cytotoxic response. Cell Immunol 67(1):129-140
133. Wang X, Chang WC, Wong CW et al (2011) A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118(5):1255-1263
134. Watanabe N, Anurathapan U, Brenner M et al (2013) Transgenic expression of a novel immunosuppressive signal converter on T Cells. Mol Ther 22(S1):S153
135. Wildeman MA, Novalic Z, Verkuijlen SA et al (2012) Cytolytic virus activation therapy for epstein-barr virus-driven tumors. Clin Cancer Res 18(18):5061-5070
136. Wilkie S, Burbridge SE, Chiapero-Stanke L et al (2010) Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem 285(33):25538-25544
137. Xue SA, Labrecque LG, Lu QL et al (2002) Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer 99(5):635-643
138. Yang L, Pang Y, Moses HL (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31(6):220-227
139. Yin Y, Manoury B, Fahraeus R (2003) Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301(5638):1371-1374